Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grifola frondosa is an edible medicinal mushroom native to East Asia, commonly known as maitake or hen-of-the-woods. It is used both as a food and a dietary supplement. Grifola frondosa contains a variety of bioactive compounds, primarily polysaccharides such as beta-glucans, glycoproteins, proteins, sterols, and phenolic compounds, which have demonstrated significant pharmacological potential. Mechanistically, its polysaccharide fractions are believed to exert effects by modulating the immune system, enhancing cellular responses through macrophage, NK cell, and T cell activation, and influencing cytokine production. Preclinical and limited clinical studies suggest it may have antitumor, antiviral, antibacterial, anti-inflammatory, antidiabetic, antihypertensive, and lipid-lowering effects. The mushroom and its extracts are marketed mainly as dietary supplements to support immune function and metabolic health, with ongoing research into roles in cancer adjunctive therapy, viral infection support, diabetes, hypertension, and PCOS. It is not a pharmaceutical drug and is not approved by regulatory agencies for treatment of any disease[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on grifola frondosa.